<?xml version="1.0" encoding="UTF-8"?>
<p>In 2012 a manufacturing process was approved by the United States Food and Drug Administration (FDA) that uses cell-culture technology for influenza vaccine production. In 2016 this process also extended to include both isolation and bulk production, which was also approved by the FDA for the development of WHO-isolated CVVs (
 <italic>versus</italic> egg-based).
 <sup>
  <xref rid="bibr4-2515135520908121" ref-type="bibr">4</xref>
 </sup> Starting in the 2017â€“2018 season, WHO has provided strain recommendations for seasonal influenza vaccines for both egg-derived and cell-derived CVVs.
 <sup>
  <xref rid="bibr25-2515135520908121" ref-type="bibr">25</xref>
 </sup>
</p>
